These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33068198)

  • 1. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
    Garcia-Tejedor A; Fernandez-Gonzalez S; Ortega R; Gil-Gil M; Perez-Montero H; Fernandez-Montolí E; Stradella A; Recalde S; Soler T; Petit A; Bajen MT; Benitez A; Guma A; Campos M; Pla MJ; Martinez E; Laplana M; Pernas S; Perez-Sildekova D; Catala I; Ponce J; Falo C
    Breast Cancer Res Treat; 2021 Feb; 185(3):657-666. PubMed ID: 33068198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.
    Fernandez-Gonzalez S; Falo C; Pla MJ; Verdaguer P; Nuñez D; Guma A; Soler T; Vethencourt A; Vázquez S; Fernandez-Montoli ME; Campos M; Pernas S; Gil M; Ponce J; Garcia-Tejedor A
    Breast J; 2020 May; 26(5):888-896. PubMed ID: 32052521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary de-escalation after neoadjuvant chemotherapy for advanced lymph node involvement in breast cancer.
    Capasso K; Mitri S; Roldan-Vasquez E; Flores R; Bhasin S; Borgonovo G; Davis RB; James T
    Am J Surg; 2024 Oct; 236():115893. PubMed ID: 39153469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of axillary ultrasound (AUS) to assess the nodal status after neoadjuvant chemotherapy (NACT) in primary breast cancer patients.
    Leinert E; Lukac S; Schwentner L; Coenen A; Fink V; Veselinovic K; Dayan D; Janni W; Friedl TWP
    Surg Oncol; 2024 Feb; 52():102016. PubMed ID: 38056112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
    Guo X; Zhang J; Gong X; Wang J; Dai H; Jiao D; Ling R; Zhao Y; Yang H; Liu Y; Liu K; Zhang J; Mao D; He J; Yu Z; Liu Y; Fu P; Wang J; Jiang H; Zhao Z; Tian X; Cao Z; Wu K; Song A; Jin F; Fan Z; Liu Z
    Breast; 2024 Feb; 73():103671. PubMed ID: 38277714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.
    Zhang GC; Zhang YF; Xu FP; Qian XK; Guo ZB; Ren CY; Yao M
    Curr Oncol; 2013 Jun; 20(3):e180-92. PubMed ID: 23737688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy in patients with breast cancer: Does response in the breast predict axillary node response?
    Morgan C; Stringfellow TD; Rolph R; Kovacs T; Kothari A; Pinder SE; Hamed H; Sever AR
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):522-526. PubMed ID: 31740186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nodal positivity in patients with clinically and radiologically node-negative breast cancer treated with neoadjuvant chemotherapy: multicentre collaborative study.
    Zaborowski AM; Doogan K; Clifford S; Dowling G; Kazi F; Delaney K; Yadav H; Brady A; Geraghty J; Evoy D; Rothwell J; McCartan D; Heeney A; Barry M; Walsh SM; Stokes M; Kell MR; Allen M; Power C; Hill ADK; Connolly E; Alazawi D; Boyle T; Corrigan M; O'Leary P; Prichard RS
    Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38055888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
    Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
    Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
    Skarping I; Förnvik D; Zackrisson S; Borgquist S; Rydén L
    Breast Cancer Res Treat; 2021 Aug; 189(1):131-144. PubMed ID: 34120224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
    Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
    Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.
    Najim O; Dockx Y; Huyghe I; van den Wyngaert T; Papadimitriou K; Tjalma WAA; Huizing MT
    Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():108-111. PubMed ID: 30145524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer.
    Ladak F; Chua N; Lesniak D; Ghosh S; Wiebe E; Yakimetz W; Rajaee N; Olson D; Peiris L
    Can J Surg; 2022; 65(1):E89-E96. PubMed ID: 35135785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axillary ultrasonography combined with pre-operative wire localisation of clipped node in nodal restaging after neoadjuvant chemotherapy in node positive breast cancer patients: a pilot study.
    Pulappadi VP; Paul S; Hari S; Dhamija E; Manchanda S; Kataria K; Mathur S; Mani K; Gogia A; Deo S
    Br J Radiol; 2021 Nov; 94(1127):20210788. PubMed ID: 34491822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
    Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.